Asset Details
Do you wish to reserve the book?
Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes
Do you wish to request the book?
Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes
2015
Overview
Background
The aim of the study was to evaluate the effect of delay in treatment intensification (IT; clinical inertia) in conjunction with glycaemic burden on the risk of macrovascular events (CVE) in type 2 diabetes (T2DM) patients.
Methods
A retrospective cohort study was carried out using United Kingdom Clinical Practice Research Datalink, including T2DM patients diagnosed from 1990 with follow-up data available until 2012.
Results
In the cohort of 105,477 patients mean HbA1c was 8.1% (65 mmol/mol) at diagnosis, 11% had a history of cardiovascular disease, and 7.1% experienced at least one CVE during 5.3 years of median follow-up. In patients with HbA1c consistently above 7/7.5% (53/58 mmol/mol, n = 23,101/11,281) during 2 years post diagnosis, 26/22% never received any IT. Compared to patients with HbA1c <7% (<53 mmol/mol), in patients with HbA1c ≥7% (≥53 mmol/mol), a 1 year delay in receiving IT was associated with significantly increased risk of MI, stroke, HF and composite CVE by 67% (HR CI: 1.39, 2.01), 51% (HR CI: 1.25, 1.83), 64% (HR CI: 1.40, 1.91) and 62% (HR CI: 1.46, 1.80) respectively. One year delay in IT in interaction with HbA1c above 7.5% (58 mmol/mol) was also associated with similar increased risk of CVE.
Conclusions
Among patients with newly diagnosed T2DM, 22% remained under poor glycaemic control over 2 years, and 26% never received IT. Delay in IT by 1 year in conjunction with poor glycaemic control significantly increased the risk of MI, HF, stroke and composite CVE.
Publisher
BioMed Central,Springer Nature B.V
Subject
/ Blood Glucose - drug effects
/ Cardiovascular Diseases - diagnosis
/ Cardiovascular Diseases - etiology
/ Cardiovascular Diseases - prevention & control
/ Diabetes
/ Diabetes Mellitus, Type 2 - blood
/ Diabetes Mellitus, Type 2 - complications
/ Diabetes Mellitus, Type 2 - diagnosis
/ Diabetes Mellitus, Type 2 - drug therapy
/ Female
/ Glycated Hemoglobin - metabolism
/ Humans
/ Hypoglycemic Agents - therapeutic use
/ Male
/ Medicine
